Eisai (OTCMKTS:ESALY) Releases FY 2023 Earnings Guidance

Eisai (OTCMKTS:ESALYGet Rating) updated its FY 2023 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $1.37-$1.37 for the period. The company issued revenue guidance of $6.03 billion-$6.03 billion.

Shares of OTCMKTS:ESALY opened at $39.90 on Friday. The firm’s 50-day simple moving average is $43.51 and its 200-day simple moving average is $50.09. The company has a quick ratio of 1.62, a current ratio of 2.04 and a debt-to-equity ratio of 0.12. Eisai has a fifty-two week low of $39.49 and a fifty-two week high of $114.16.

Separately, Zacks Investment Research downgraded shares of Eisai from a hold rating to a strong sell rating in a report on Wednesday.

Eisai Company Profile (Get Rating)

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Read More

Earnings History and Estimates for Eisai (OTCMKTS:ESALY)

Want More Great Investing Ideas?

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.